Mixed activated killer (MAK) immune cells

混合活化杀伤（MAK）免疫细胞

Report date: 2026/01/04 20:00:05

Base Information

Drug NameMixed activated killer (MAK) immune cells
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy
Mechanisms of ActionUpdating
TargetsUpdating
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesBeijing Tuohua Weiye Biotechnology Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesBeijing Tuohua Weiye Biotechnology Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumours
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A